Loading…
← CockpitCompetitor Analysis › 9996.HK Peijia Medical Ltd.Open in the cockpit ↗

Peijia Medical Ltd.9996.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum weak 23
Mkt cap
$296M
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$450,116
20-day average traded
Fwd P/E
292.4×
forward earnings
ROIC−WACC
-14.3 pp
WACC 9.4%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$3.57
1D-3.4%
1W-10.2%
1M-17.4%
3M-26.0%
6M-33.8%
YTD-40.6%
1Y-38.8%
ATR %7.0%
52w lowhigh51.6% off high

What Peijia Medical does

Employees: 1,022

Peijia Medical at a glance

Size Peijia Medical (9996.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $296M, the 885th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.57 on 18 Nov 2026.

Performance Over six months the shares fell 33.8%, against -15.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 21.2% over the last twelve months (peer median +2.2%); the operating margin is -13.3% (peer median 9.4%).

Valuation It trades at 292.4× forward earnings against a peer median of 17.1× (2nd most expensive of 13).

Capital Return on invested capital runs 14.3 points below its cost of capital (9.4% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 869996.HK 69
Six months, rebased to 100: Peijia Medical against the median of its 20 peers (local-currency closes).

Peijia Medical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$877MHK$773MHK$667MHK$487MHK$292M
Revenue growth—+16%+37%+67%—
Gross profitHK$580MHK$483MHK$433MHK$335MHK$185M
EBITDA-HK$36.0M-HK$160M-HK$206M-HK$433M-HK$612M
Net income-HK$155M-HK$220M-HK$246M-HK$434M-HK$474M
Free cash flow-HK$90.5M-HK$262M-HK$247M-HK$845M-HK$592M
Capital expenditureHK$205MHK$330MHK$304MHK$349MHK$235M
Total debtn/aHK$495MHK$270MHK$258MHK$148M

Quarterly statements and history in the cockpit →

Peijia Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-10%0%SMTI6885766883145889300942300753197A301502377740688273CLTNYDESEMBCVBSN3006536883381609SBSCV9996.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Peijia Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×250×500×750×SMTI6885765889300753197A377740688273CLTNEMBC3006539996.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Peijia Medical is the large dot.

Peijia Medical competitors and peer comparison

How Peijia Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Peijia Medical against its 20 peers (data as of 18 Nov 2026)
Measure9996.HKPeer medianRank in peer set
1-month return-17.4%-8.6%2nd lowest of 21
6-month return-33.8%-15.9%7th lowest of 21
Distance from 52-week high-51.6%-45.3%9th lowest of 21
Revenue growth (TTM)+21.2%+2.2%2nd highest of 21
Operating margin-13.3%9.4%4th lowest of 21
Forward P/E292.4×17.1×2nd most expensive of 13
ROIC minus cost of capital-14.3 pp+5.4 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Peijia Medical 9996.HKHong Kong$296M-34%+21%-13%292.4×n/an/a
Sanara MedTech SMTIUnited States$301M+42%+10%11%59.0×19.5%+45.9%
Chongqing Xishan Science and Technology 688576.SSChina$301M-40%-23%-29%12.8×n/an/a
Kontour (Xi'an) Medical Technology 688314.SSChina$291M-46%+8%24%n/a3.1%+16.4%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a

Questions

Which companies are Peijia Medical's closest peers?
The cockpit's peer set: Sanara MedTech (SMTI), Chongqing Xishan Science and Technology (688576.SS), Kontour (Xi'an) Medical Technology (688314.SS), Japan Eyewear (5889.T), Shenzhen Bioeasy Biotechnology (300942.SZ), Jiangsu Apon Medical Technology (300753.SZ), Chemclin Diagnostics (688468.SS), Tauns Laboratories (197A.T).
Is Peijia Medical expensive compared with its peers?
On forward p/e it trades at 292.4× against a peer median of 17.1×, 2nd most expensive of 13 in its peer set.
How has Peijia Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -33.8% against -15.9% for the median peer; over one year -38.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.